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Hypoxia-inducible factor-1
alpha (HIF-1alpha)The mechanisms involved in the neuroprotection induced by hypoxic preconditioning (HP) have not been
fully elucidated. The involvement of hypoxia-inducible factor-1 alpha (HIF-1alpha) in such neuroprotection
has been conﬁrmed. There is also evidence showing that a series of genes with important functions in iron
metabolism, including transferrin receptor (TfR1) and divalent metal transporter 1 (DMT1), are regulated
by HIF-1alpha in response to hypoxia in extra-neural organs or cells. We therefore hypothesized that HP is
able to affect the expression of iron metabolism proteins in the brain and that changes in these proteins in-
duced by HP might be associated with the HP-induced neuroprotection. We herein demonstrated for the ﬁrst
time that HP could induce a signiﬁcant increase in the expression of HIF-1alpha as well as iron uptake (TfR1
and DMT1) and release (ferroportin1) proteins, and thus increase tansferrin-bound iron (Tf-Fe) and non-
transferrin-bound iron (NTBI) uptake and iron release in astrocytes. Moreover, HP could lead to a progressive
increase in cellular iron content. We concluded that HP has the ability to increase iron transport speed in as-
trocytes. Based on our ﬁndings and the importance of astrocytes in neuronal survival in hypoxic/ischemic
preconditioning, we proposed that the increase in iron transport rate and cellular iron in astocytes might
be one of the mechanisms associated with the HP-induced neuroprotection. We also demonstrated that fer-
roportin1 expression was signiﬁcantly affected by HIF-1alpha in astrocytes, implying that the gene encoding
this iron efﬂux protein might be a hypoxia-inducible one.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Preconditioning induced by hypoxia can produce signiﬁcant pro-
tective effects on neurons in experimental cells, animals and humans
[1–6]. The involvement of hypoxia-inducible factor-1 alpha (HIF-
1alpha) and the increased expression of its target genes in the neuro-
protection induced by hypoxic preconditioning (HP) have been well
conﬁrmed. In addition, adaptation to hypoxia of cells and tissues
leads to the transcriptional induction of a series of genes, several of
which have important functions in iron metabolism [7]. Transferrin
(Tf) and transferrin receptor (TfR1) are two key proteins involved
in iron uptake by mammalian cells [8]. Hypoxia can increase iron
uptake by cells as well as the expression of Tf and TfR1, both of
which have been identiﬁed as hypoxia-inducible genes [9–11]. It
has also been reported that several other iron transport or regulation
proteins, including ceruloplasmin (Cp) [12], iron regulatory protein 1
(IRP1) [13] and 2 (IRP2) [14], and hepcidin [15], are regulated by HIF-
1 in response to hypoxic conditions. Our recent studies [16,17] haveciences, Faculty of Medicine,
l rights reserved.demonstrated that divalent metal transporter 1 (DMT1) is a hypoxia-
inducible gene.
Currently, we know very little about the effects of HP on the expres-
sion of iron transport proteins in the brain. Moreover, the mechanisms
involved in the neuroprotection induced by hypoxic preconditioning
(HP) have not yet been fully elucidated. Based on the foregoing ﬁndings
about the effects of HP on the expression of iron metabolism proteins
obtained from the extra-neural organs or cells, we speculated that HP
is also able to affect the expression of iron metabolism proteins in the
brain. We hypothesized that the responses of iron metabolism proteins
in astrocytes or other brain cells to HPmight be associated with the HP-
induced neuroprotection. We also proposed that the expression of fer-
roportin1 (Fpn1), a key iron efﬂux protein, might be regulated by HIF-
1alpha. In this study, we therefore investigated systematically the
effects of HP on the expression of iron transport proteins in primary cul-
tured astrocytes. Astrocytes were chosen in this study because of their
importance in neuronal survival in the post-ischemic period [18], and
because of their key function as a central integrator in the brain [19].
We demonstrated for theﬁrst time thatHP could induce a signiﬁcant in-
crease in the expression of iron uptake (TfR1 and DMT1) and release
(Fpn1) proteins and thus speed up the rate of iron transport in astro-
cytes, and proposed that the increase in the rate of iron transport in as-
trocytes might be one of the mechanisms involved in the
neuroprotection induced by HP.
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2.1. Materials
Unless otherwise stated, all chemicals were obtained from Sigma
Chemical Co., St. Louis, MO, USA. The mouse anti-rat TfR1 monoclonal
antibodywas obtained from Zymed Laboratories, South San Francisco,
CA, USA and antibodies against DMT1 with (DMT1+IRE) or without
(DMT1− IRE) iron response element and Fpn1 were purchased from
Alpha Diagnostic International Company, San Antonio, TX, USA. The
primary monoclonal mouse anti-HIF-1alpha was obtained from
Novus Biologicals, Littleton, CO, US. Goat anti-rabbit or anti-mouse
IRDye 800 CW secondary antibodies were purchased from LI-COR
Biosciences, Lincoln, NE, USA. The speciﬁc antibody against astrocyte
glial ﬁbrillary acidic protein (GFAP) was purchased from Chemicon
International Ltd, UK. Bradford assay kit was bought from Bio-Rad,
Hercules, CA, USA and
55
FeCl3 from Perkin-Elmer Company, Wellesley,
MA, USA. The Health Department of Hong Kong Government and the
Animal Ethics Committee of the Chinese University of Hong Kong ap-
proved the use of animals for this study.
2.2. Primary cortical astrocyte culture
All experiments were carried out with cortical astrocytes prepared
from newborn SD rats at postnatal 1–3 days by a procedure previous-
ly described [20,21] with minor modiﬁcations. Cortices were cut into
small cubes (b1 mm3) and digested with 0.125% trypsin for 15 min at
37 °C. Trypsinization was terminated by the addition of Dulbecco's
modiﬁed Eagle's medium (DMEM, Gibco, USA) containing 10% fetal
bovine serum (FBS, Hyclone, Logan, UT, USA) and antibiotics (penicil-
lin 100 U/ml, streptomycin 100 μg/ml). Cell suspensions were passed
through a 40 μm cell strainer. The ﬁltrate was allowed pre-adherence
for 1 h to remove any contamination from ﬁbroblasts before being
seeded at a density of 1×106/ml in 25 or 50 cm2 ﬂasks. The cells
were then incubated in a 5% CO2 incubator at 37 °C. After the cultures
reached conﬂuence (for about 7 days), the cells were subcultured and
allowed pre-adherence for 30 min in the subculture process. The
puriﬁed astrocytes were seeded on 6, 12, 24 or 96-well plates pre-
coated with poly-L-lysine at a density of 1×106/ml and cultured for
another 7 days before use. The purity of the astrocytes was assessed
as the percentage of cells with GFAP (1:5000), which was approxi-
mately 99%.
2.3. Experimental design
To investigate the effects of hypoxic preconditioning (HP) on the ex-
pression of iron transport proteins (TfR1, DMT1 and Fpn1) as well as
iron uptake and release in primary astrocyte culture, the cells in DMEM
without serumwere exposed to hypoxia (1%O2) in a dedicated incubator
(NAPCO 7101FC-1)with 1%O2, 94%N2 and 5% CO2 at 37 °C for 0, 1, 2, 4 or
12 h. To investigate the effect of hypoxic preconditioning/re-oxygenation
(HP/R), the astrocytes were exposed to hypoxia (1% O2) for different du-
rations as mentioned earlier, and then exposed to nomoxia (21% O2) for
24 h. After treatment with HP or HP/R, cell viabilities were assayed by a
MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl-monotetrazolium bro-
mide, BDH Chemicals Ltd., England.) assay, protein contents of TfR1,
DMT1, Fpn1 and HIF-1alpha were determined by western blot analysis,
and transferrin-bound iron (Tf-Fe) and non-transferrin-bound iron
(NTBI) entry into and iron release from astrocytes were determined by
radioisotope measurements.
2.4. Cell viability
The cell viability was assessed using a MTT assay in which the yel-
low MTT is reduced to a purple formazan by mitochondrial dehydro-
genase in live cells as described previously [22]. Brieﬂy, a total of25 ml MTT (1 g/l in phosphate-buffered saline, PBS) was added and
another 4 h of incubation at 37 °C was conducted. The assay was
stopped by the addition of 100 ml lysis buffer (20% SDS in 50% N0N-
dimethylformamide, pH 4.7). Optical density (OD) was measured at
the 570 nm wavelength by the use of an ELX-800 microplate assay
reader (Elx800, Bio-tek, USA). Results were expressed as a percentage
of absorbance measured in the control cells.
2.5. Measurement of total iron content in astrocytes
The astrocytes were dissolved in 50 mMNaOH (100 μl/well, 6-well
plate) and a 50 μl aliquot was subjected to detection of cellular protein
concentration. Standard curves ranging from 0 to 40 ppb were con-
structed by diluting iron standard (1 mg iron/ml, Alpha Products,
Danvers, MA). Both standards and samples were read in triplicate by
injecting 50 μl aliquots into the graphite furnace of the GFAAS ma-
chine (Perkin Elmer SIMAA 6000, Rautaruukki Ltd., Raahe, Finland).
Iron analyses (absorbance readings) were recorded at 248.3 nm, slit
at 0.2 nm, with pretreatment temperature at 1400 °C and atomization
temperature at 2400 °C. Iron content could be calculated from the
standard curves and intracellular iron contents were further normal-
ized with the cellular protein concentrations.
2.6. Western blot analysis
Western blot analysis was performed as described previously
[23,24]. The proteins were extracted with 150 ml cold lysis buffer
(50 mmol/l Tris–HCl with pH 6.8, 1 mmol/l EDTA, 1% SDS, 1% Nonide
P-40, 1 mmol/l Na3VO4, 1 mmol/l NaF, 5% bmercaptoethanol,
0.4 mmol/l phenylmethylsulfonyl ﬂuoride (PMSF), 2 mg/l Aprotinin,
2 mg/l Leupeptin, and 2 mg/l Pepstain). Lysates were kept in ice for
30 min and centrifuged at 12,000 rpm at 4 °C for 15 min. The super-
natant was collected and the protein content was determined using
the Bradford assay kit. A total of 30 μg protein (for detecting TfR1,
Fpn1, DMT1+IRE and DMT1− IRE) or 120 μg protein (for detecting
HIF-1alpha) was separated by 10% SDS-polyacrylamide gels (SDS-
PAGE), transferred to the polyvinylidene diﬂuoride (PVDF) mem-
branes (Bio-Rad, Hercules, CA, USA) previously blocked with 5%
non-fat milk in 20 mM TBS-T (Tris-buffered saline with pH 7.5 and
0.1% Tween-20), and incubated overnight at 4 °C with the indicated
primary monoclonal mouse anti-HIF-1alpha (1:500), rabbit anti-rat
DMT1+IRE (1:5000), DMT1− IRE1 (1:5000), mouse anti-rat TfR
monoclonal antibody (1:2500), and rabbit anti-mouse Fpn1
(1:5000) overnight at 4 °C, and then incubated with the goat anti-rabbit
(for detecting DMT1+IRE, DMT1−IRE and Fpn1) or anti-mouse (for
detecting TfR1 and HIF-1alpha) IRDye 800 CW secondary antibody
(1:5000) for 1 h at room temperature. To ensure even loading of the sam-
ples, the samemembrane was probed with rabbit anti-rat β-actin mono-
clonal antibody at 1:20,000 dilutions for 6 h and then incubated with the
goat anti-mouse IRDye 800 CW secondary antibody for 30 min. Proteins
were visualized using an Odyssey scanner and the intensities of the spe-
ciﬁc bandswere analyzed byOdyssey infrared imagine system,with a res-
olution of 169 μm (Odyssey infrared imagine system).
2.7. Transferrin-bound iron uptake by astrocytes
Transferrin-bound iron (
55
Fe-Tf) solution was prepared as previ-
ously described [25]. After different treatments, the astrocytes were
incubated with 2 μM of
55
Fe-Tf in 0.5 ml serum-free DMEM medium
at 37 °C for 30 min with gentle shaking. After that, they were washed
with cold PBS twice and all un-bound Tf was stripped with an acid
buffer (0.2 N acetic acid, 500 mM NaCl, 1 mM FeCl3). The cells were
then lysed with 500 μl lyses buffer and a 10 μl aliquot was subjected
to detection of protein concentration. The cytosol was separated
from the membrane by centrifugation at 10,000 g at 4 °C for 20 min,
and the pellet (membrane fraction) was dissolved with 490 μl of 1%
Fig. 1. Effects of hypoxic preconditioning on cell viabilities. The astrocytes were treated
with hypoxic preconditioning (HP) for 0 (Control), 1, 2, 4 or 12 h with or without re-
oxygenation (R) (24 h) as described in the “Experimental design”. Cell viabilities
were then assayed by a MTT assay. A: Effects of HP, B: Effects of HP/R. Data are pre-
sented as mean±SEM (n=5). *Pb0.05 vs. the control.
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the cpm separately. The sum of the radioactivity in the cytosol and
the membrane was referred to as the total cellular radioactivity. The
cellular radioactivity was the total cellular radioactivity divided by
the protein amount [i.e., cellular radioactivity=the sum of the radio-
activity in the cytosol and the membrane (cpm)/protein amount
(μg)], and the cpm value of each group was normalized with the indi-
vidual control group which was taken as 100%.
2.8. Non-transferrin-bound iron uptake by astrocytes
The radio-labeled
55
Fe (NTBI) solution was prepared according to
Qian and Morgen [26]. After different treatments, the astrocytes were
incubated with 1.0 μM
55
FeCl3 in 0.5 ml serum-free DMEM medium at
37 °C for 30 min with gentle shaking. After that, they were washed
with cold PBS twice and lysed with 500 μl of lyses buffer (1% SDS) and
a 10 μl aliquot was subjected to detection of protein concentration.
Threeml of scintillation solution were added to the remnant lysed frac-
tion to count the cpm. The cellular radioactivity was deﬁned as cellular
radioactivity (cpm)/protein amount (μg), and the cpm value of each
group was normalized with the individual control group.
2.9. Iron release assay
Iron release from astrocytes was measured as previously described
[27]. The
55
Fe solution was freshly prepared according to Qian and
Morgen [26]. After washing with PBS three times, the astrocytes were
incubated with 0 or 2 μMof
55
Fe solution at 37 °C for 60 min with gentle
shaking. The cellswere thenwashed twicewith PBS and treatedwithHP
or HP/R as described in the “Experimental design”. After that, the medi-
umwas collected and the cells were lysed. The radioactivity of both frac-
tions was assayed by a scintillation counter (Perkin-Elmer) as cpm. The
relative percentage of the radioactivity in the medium and in the cells
was calculated. The percentage of
55
Fe (II) release was calculated with
the following equation:
55
Fe (II) release (%)=[(cpm in medium)/(cpm
in medium+cpm in cells)]×100%. Each treatment group was normal-
ized with the individual control group.
2.10. Statistical analysis
Statistical analyses were performed using SPSS 10.0. Data are pre-
sented as mean±SEM. The difference between means was deter-
mined by one-way ANOVA followed by a Student–Newman–Keuls
test for multiple comparisons. A probability value of Pb0.05 was
taken to be statistically signiﬁcant.
3. Results
3.1. Effects of hypoxic preconditioning on cell viabilities
The effects of different durations of HP (0, 0.5, 1, 2, 4 or 12 h) orHP/R
(0, 0.5, 1, 2, 4 or 12 h/24 h) on cell viability were ﬁrst investigated in as-
trocytes. TheMTT assay results (Fig. 1) indicated that HP induced a pro-
gressive increase in cell viability from HP-0.5 h to HP-4 h. The cell
viability in the HP-2 h and HP-4 h was signiﬁcantly higher than that in
the control (Pb0.05). The further increase in the time of HP (HP-12 h)
induced a signiﬁcant reduction in cell viability as compared with HP-
4 h. The cell viability in the HP-12 h was signiﬁcantly lower than that
in HP-4 h (Pb0.05), but not signiﬁcantly different from the control. Un-
like what we found in the HP-treated astrocytes, treatment with HP/R
did not induce any signiﬁcant effects on cell viability during the period
from HP-0.5 h/R-24 h to HP-4 h/R-24 h. There were no signiﬁcant dif-
ferences among the groups of HP-0.5 h/R-24 h, HP-1 h/R-24 h, HP-2 h/
R-24 h and HP-4 h/R-24 h with the control. However, with the increase
in the time of treatments, HP-12 h/R-24 h also induced a signiﬁcantreduction in cell viability. The viability of the cells treated with HP-12/
R-24 h was signiﬁcantly lower that in the control (Pb0.05).
3.2. Hypoxic preconditioning induced a signiﬁcant increase in TfR1
expression and Tf-Fe uptake in astrocytes
We then investigated the effects of HP or HP/R on the expression of
a major iron uptake protein TfR1 as well as Tf-Fe uptake in astrocytes.
It was found that treatments of astrocytes with HP induced a progres-
sive increase in TfR1 expression as well as Tf-Fe uptake during the pe-
riod from HP-0.5 h to HP-4 h (Fig. 2A, B and D). The TfR1 expression
and Tf-Fe uptake in the cells treated with HP-0.5 h, HP-1 h, HP-2 h or
HP-4 h all were signiﬁcantly higher than those in the control
(Pb0.05). The further increase in the time of HP (HP-12 h) induced a
signiﬁcant reduction not only in TfR1 expression but also in Tf-Fe up-
take. Both the TfR1 expression and Tf-Fe uptake in the HP-12 h were
signiﬁcantly lower than those in the HP-4 h (Pb0.05), but they were
still signiﬁcantly higher than those in the control. Moreover, treat-
ments with HP/R induced a progressive increase in TfR1 expression
as well as Tf-Fe uptake in astrocytes (Fig. 2A, C and E). The TfR1 ex-
pression and Tf-Fe uptake in the astrocytes treated with HP/R at all
time points we had examined were signiﬁcantly higher than those in
the control (Pb0.05). The highest expressions of TfR1 and Tf-Fe uptake
were found in the cells treatedwith HP-12 h/R-24 h. The tendencies in
the effect of HP or HP/R on Tf-Fe uptake were very similar to those on
TfR1 expression. This implies that Tf-Fe uptake wasmainly dependent
on TfR1 expression in astrocytes treated with HP or HP/R.
3.3. Hypoxic preconditioning induced a signiﬁcant increase in DMT1
expression and NTBI uptake in astrocytes
DMT1 is anothermajor iron uptake protein. Thereforewe also inves-
tigated the effects of HP or HP/R on the expression of this protein and on
NTBI uptake in astrocytes as well. Treatments of astrocytes with HP-
0.5 h, HP-1 h or HP-25 h induced a signiﬁcant increase in the expression
Fig. 2. Hypoxic preconditioning induced a signiﬁcant increase in TfR1 expression and Tf-Fe uptake in astrocytes. The astrocytes were treated with hypoxic preconditioning (HP) for
0 (Control), 1, 2, 4 or 12 h with or without re-oxygenation (R) (24 h) as described in the “Experimental design”, then TfR1 expression was determined by western blot analysis (A, B
and C) and Tf-Fe uptake (D and E) by astrocytes by the radioisotope measurements. Data are presented as mean±SEM (n=6). *Pb0.05 vs. the control.
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contents of DMT1+IRE and DMT1− IRE in the cells treated with HP-
0.5 h, HP-1 h or HP-2 h were signiﬁcantly higher than those in the cor-
responding controls. The highest expression of both DMT1+IRE and
DMT1− IRE was found in the cells treated with HP-1 h. However, the
further increase in the time of HP induced a progressive decrease in
the expression of DMT1+IRE (Fig. 3A and B) as well as DMT1− IRE
(Fig. 3D and E). Although the contents of DMT1+IRE in the cells treated
withHP-4 h andDMT1− IRE in the cells treatedwithHP-4 h or HP-12 h
were still higher than those in the corresponding controls, no signiﬁcant
differences were found between these groups and the controls.
Furthermore, treatments of astrocytes with HP induced a progres-
sive increase in NTBI uptake by astrocytes during the earlier stage: HP-
0.5 h to HP-2 h (Fig. 3G). The NTBI uptake by the cells treatedwith HP-
0.5 h, HP-1 h or HP-2 h was signiﬁcantly higher than that in the
control cells. The highest NTBI uptake was found in the cells treated
with HP-2 h. However, the further increase in the time of HP (HP-2 h
to HP-12 h) induced a progressive decrease in NTBI uptake by astro-
cytes. Although NTBI uptake in the astrocytes treated with HP-4 h or
HP-12 h was signiﬁcantly higher than that in the controls (Fig. 3G)while DMT1+IRE and DMT1− IRE in these HP cells were not signiﬁ-
cantly different from those of the control (Fig. 3A, B, D and E), the
tendencies in the effects of HP on NTBI uptake (Fig. 3G) were basically
similar to those on the expression of DMT1+IRE (Fig. 3A and B) and
DMT1− IRE (Fig. 3D and E) in astrocytes (Fig. 3G). This might suggest
that NTBI uptake was mainly determined by the the expression of
DMT1+IRE and DMT1− IRE in the HP-treated astrocytes.
Unlike what we had found in the HP-cells, treatment of astrocytes
with HP/R did not induce any signiﬁcant changes in the expression of
DMT1+IRE (Fig. 3A and C), DMT-IRE (Fig. 3D and F) or NTBI uptake
(Fig. 3H). There were no signiﬁcant differences between the levels
of the two forms of DMT1 between all the HP/R groups and their
corresponding controls. Moreover, no signiﬁcant differences were
found between NTBI uptake by all HP/R cells and their control cells.
3.4. Hypoxic preconditioning induced a signiﬁcant increase in Fpn1
expression and iron release in astrocytes
We also investigated the effect of HP or HP/R on the expression of
Fpn1, a newly discovered trans-membrane iron export protein, and
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Fig. 4. Hypoxic preconditioning induced a signiﬁcant increase in Fpn1 expression and iron release in astrocytes. The astrocytes were treated with hypoxic preconditioning (HP) for
0 (Control), 1, 2, 4 or 12 h with or without re-oxygenation (R) (24 h) as described in the “Experimental design”, then the expression of Fpn1 was determined by western blot anal-
ysis (A, B and C) and iron release from astrocytes by the radioisotope measurements (D and E). Data are presented as mean±SEM (n=6). *Pb0.05 vs. the control.
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well documented [28,29]. Our ﬁndings demonstrated for the ﬁrst time
that HP could induce a progressive increase in the expression of Fpn1
during the period from HP-0.5 h to HP-2 h (Fig. 4A and B). The con-
tents of Fpn1 in the cells treated with HP-0.5 h, HP-1 h, HP-2 h or
HP-4 hwere signiﬁcantly higher than those in the control. The highest
expression of Fpn1was found in the cells treatedwith HP-2 h. Howev-
er, the further increase in the time of HP (HP-2 h to HP-12 h) induced
a progressive decrease in Fpn1 expression (Fig. 4A and B). There were
no signiﬁcant differences in Fpn1 expression between the HP-12 h
cells and the control. The tendencies in the effect of HP on iron release
(Fig. 4D) were very similar to those on Fpn1 expression. In consistent
with the effect on Fpn1 expression, iron release in the cells treated
with HP-0.5 h, HP-1 h, HP-2 h or HP-4 h was also signiﬁcantly higher
than that in the control and the highest release of iron was found inFig. 3.Hypoxic preconditioning induced a signiﬁcant increase inDMT1 expression andNTBI upta
trol), 1, 2, 4 or 12 hwith or without re-oxygenation (R) (24 h) as described in the “Experimenta
determined by western blot analysis and NTBI uptake (G and H) by astrocytes by the radioisotothe cells treated with HP-2 h. This implies that Fpn1 is a major factor
to determine iron release in astrocytes treatedwith HP. However, con-
trary to what we had found in the HP cells, treatments of astrocytes
with HP/R did not induce any signiﬁcant changes in Fpn1 expression
(Fig. 4A and C) or also iron release (Fig. 4E). There were no signiﬁcant
differences in Fpn1 expression and iron release from astrocytes be-
tween all HP/R groups and their corresponding controls.
3.5. Hypoxic preconditioning induced a signiﬁcant increase in the con-
tents of hypoxia-inducible factor-1 alpha and iron in astrocytes
To ﬁnd out the possible connection between HIF-1 and iron trans-
port, we investigated the effects of HP or HP/R on the levels of HIF-
1alpha and iron contents in astrocytes. It was found that HP induced
a progressive increase in the contents of HIF-1alpha during the periodke in astrocytes. The astrocyteswere treatedwith hypoxic preconditioning (HP) for 0 (Con-
l design”, then the expression of DMT1+IRE (A, B and C) and DMT1− IRE (D, E and F) was
pe measurements. Data are presented as mean±SEM (n=6). Pb0.05 vs. the control.
506 L. Yang et al. / Biochimica et Biophysica Acta 1822 (2012) 500–508fromHP-0.5 h to HP-4 h (Fig. 5A). However, the further increase in the
time of HP (HP-12 h) induced a signiﬁcant decrease in HIF-1alpha. The
content of HIF-1alpha in the group of HP-12 h was signiﬁcantly lower
than that in the group of HP-4 h and also not signiﬁcantly different
from the control. In the cells treated with HP/R, no signiﬁcant differ-
ences were found in the levels of HIF-1alpha among the control and
all HP/R groups (Fig. 5B). Iron contents in astrocytes were found to
have increased progressively with the increase in the time of HP
(Fig. 5C) or HP/R (Fig. 5D) although there were no signiﬁcant differ-
ences among the groups of HP-0.5 h, HP-1 h, HP-2 h, HP-4 h and the
control in the HP astrocytes (Fig. 5C) and the groups of HP-0.5 h/R-
24 h and the control in the HP/R cells (Fig. 5D).
4. Discussion
Although it has been conﬁrmed that a series of genes with impor-
tant functions in iron transport, including TfR1 [9–11] and DMT1
[16,17], in extra-neural organs and cells are hypoxia-inducible genes,
very little is known about the effects of HP on the expression of
these proteins in the brain. Moreover, the mechanisms of the neuro-
protection induced by HP have not yet been fully elucidated although
the involvement of HIF-1alpha is conﬁrmed. One of the major objec-
tives of this study was to determine whether HP could affect the ex-
pression of iron transport proteins and iron transport in astrocytes
as had been found outside of the brain. Our ﬁndings demonstratedFig. 5. Hypoxic preconditioning induced a signiﬁcant increase in the contents of hypoxia-in
preconditioning (HP) for 0 (Control), 1, 2, 4 or 12 h with or without re-oxygenation (R) (2
determined by western blot analysis (A and B) and iron contents in the astrocytes by a GFAAfor the ﬁrst time that HP has the ability to induce a signiﬁcant increase
in the expression of iron uptake (TfR1 and DMT1) and release (Fpn1)
proteins, and thus increase transferrin-bound iron (Tf-Fe) and non-
transferrin-bound iron (NTBI) uptake and iron release in astrocytes
in addition to the increased cellular iron content, cell viability and ex-
pression of HIF-1alpha in cells. It has been well determined that astro-
cytes function as a central integrator in the brain [18] and play an
important role in neuronal survival in the post-ischemic period [19].
Moreover, iron is a transition metal essential for oxygen transport,
cell growth and survival [16]. The increase in the availability of cellular
iron might be able to promote the synthesis of iron-associated mole-
cules involved in oxygen transport and then increase the abilities of
oxygen transport and the availability of oxygen in astrocytes. There-
fore, the increase in the rate of iron transport and cellular iron in astro-
cytesmight be one of themechanisms involved in the neuroprotective
role or the increased anoxic tolerance.
Both TfR1 and DMT1 are hypoxia-inducible genes [9–11]. In the HP
astrocytes, we found a signiﬁcant increase in the expression of not
only iron uptake (TfR1 and DMT1) and release (Fpn1) proteins but
alsoHIF-1alpha. This implies that the increased expression of iron trans-
port proteins is probably due to the increased expression of HIF-1alpha.
However, it was noticed that the tendencies in the effects of HP on the
expression of HIF-1alpha are very similar to those on TfR1, but not to
those on DMT1 and Fpn1. The HP induced a progressive increase in the
expression of HIF-1alpha, and the highest expression was found in HP-ducible factor-1 alpha and iron in astrocytes. The astrocytes were treated with hypoxic
4 h) as described in the “Experimental design”, then the expression of HIF-1alpha was
S method (C and D). Data are presented as mean±SEM (n=6). *Pb0.05 vs. the control.
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and Fpn1was in HP-1 h andHP-2 h respectively. These results imply that
HIF-1alpha plays a predominant role in TfR1 expression, but not in DMT1
or Fpn1 expression in the HP cells. There might be other factors that are
also involved in the control of DMT1 and Fpn1 regulation in additon to
HIF-1alpha in the astrocytes treated with HP.
However, the responses of the expression of HIF-1alpha, TfR1, DMT1
and Fpn1 to HP/R are different from those to HP. In the HP/R cells, no
signiﬁcant changes were found in the expression of HIF-1alpha, DMT1
(DMT1+IRE and DMT1− IRE) or Fpn1. Accordingly, treatment with
HP/R did not induce any signiﬁcant effect on NTBI uptake or iron release
in astrocytes. The similar tendencies in the effects of HP/R on the ex-
pression of HIF-1alpha as well as DMT1 (NTBI uptake) and Fpn1 (iron
release) might suggest that the expression of DMT1 and Fpn1 is mainly
controlled by HIF-1alpha in the HP/R cells. However, TfR1 expression
and Tf-Fe uptake were found to have increased with the time of HP/R
treatments although HIF-1alpha did not respond to HP/R treatment.
The inconsistency in the responses of the expression of HIF-1alpha
and TfR1 to HP/R treatment showed that HIF-1alpha is not the only or
major factor to regulate TfR1 expression in the HP/R cells. HR/P treat-
mentmight induce somemolecules that can produce a signiﬁcant effect
on the expression of TfR1 in astrocytes. In both of the HP andHP/R cells,
the cellular iron contents increased with the time of treatments, how-
ever, iron levels in the HP/R cells were relatively higher than those in
the HP cells at almost all time points we measured. This was probably
due to the increased expression of Fpn1 and then iron release in the
HP cells while the expression of Fpn1 did not respond to the HR/P.
In addition, HIF-1alpha is very sensitive to oxygen availability. In the
HP/R cells, HIF-1alpha might be up-regulated under HP and then
returned to the control level after “R”. Its up-regulation under HP may
stimulate a numbers of target genes, some of which may be long-
lasting such as TfR1 (and Tf-Fe uptake), while the others including
DMT1 (and NTBI) may not in terms of the expression and/or function
of these genes after HIF-1alpha stimulation. This possibility might also
be associated with the inconsistency in the responses of the expression
of HIF-1alpha, DMT1 (DMT1+IRE andDMT1− IRE), Fpn1 and TfR1 and
also cellular iron levels to HP and HP/R treatments.
It is currently completely unknown whether the expression of
Fpn1 is regulated by hypoxic preconditioning in the brain. In this
study, we presented evidence for the ﬁrst time that Fpn1 expression
in astrocytes was signiﬁcantly affected by HP, but not HP/R. Moreover,
HP, but not HP/R, induced a signiﬁcant effect on HIF-1alpha expression
in the cells. These ﬁndings might imply that the gene encoding this
iron efﬂux protein might be a hypoxia-inducible one. This possibility
needs further investigations.
In summary, we investigated the effects of HP and HP/R on the ex-
pression of iron transport proteins as well as HIF-1alpha in astrocytes.
We demonstrated for the ﬁrst time that HP could induce a signiﬁcant
increase in the expression of HIF-1alpha as well as iron uptake (TfR1,
DMT1− IRE and DMT1+IRE) and release (Fpn1) proteins, and thus
increase Tf-Fe and NTBI uptake and iron release, and also a progressive
increase in cellular iron content. We concluded that HP has the ability
to speed up the rate of iron transport in astrocytes and proposed that
the increase in the rate of iron transport and cellular iron in astrocytes
might be one of the mechanisms involved in the neuroprotective role
or the increased anoxic tolerance induced by HP.
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